Table 2. Phenotyping drug resistance profiles for first-line drugs among confirmed EPTB patients by patient history profile, 2020.
| Drug resistance pattern | Isolates from new cases, n (%) | Isolates from previously treated cases, n % | Total n (%) |
|---|---|---|---|
| Total tested Isolate | 137 | 14 | 151 |
| Susceptible | 115(83.9) | 7(50.0) | 122(80.8) |
| Resistance to any drug | |||
| STM | 7(5.1) | 2(14.2) | 9 (6.0) |
| INH | 19(13.8) | 3(21.4) | 22 (14.6) |
| RIF | 11(8.0) | 3(21.4) | 14 (9.3) |
| EMB | 3(2.2) | - | 3 (2.0) |
| PZA | 19(13.9) | 3(21.4) | 22(14.6) |
| Mono resistance | |||
| INH | 2(1.5) | 1(7.1) | 3 (2.0) |
| PZA | 8(5.8) | 1(7.1) | 9(5.9) |
| Resistance to more than one drug | |||
| INH + RIF | 11(8.0) | 3(21.4) | 14(9.3) |
| INH + PZA | 12(8.6) | 3(21.4) | 15(9.9) |
| INH + STM | 7(5.1) | 2(14.3) | 9(6.0) |
| INH + EMB | 3(2.2) | - | 3(1.32) |
| INH + RIF + STM | 4(2.9) | 1(7.1) | 5(3.3) |
| INH + RIF + EMB | 2(1.5) | - | 2(1.3) |
| INH + RIF + PZA | 8(5.8) | 2(14.3) | 10(6.6) |
| INH + RIF + EMB + PZA | 1(0.7) | - | 1(0.7) |
| STM + INH + RIF + PZA | 4(2.9) | 1(7.1) | 5(3.3) |
| INH + RIF or MDR | 11(8.0) | 3(21.4) | 14 (9.3) |
STM-Streptomycin, INH-Isoniazid, RIF-Rifampicin, EMB-Ethambutol, PZA-Pyrazinamide, MDR-Multi drug resistance.